Study flow chart: generation of allocation sequence, enrollment and assignment was done by AD.

<p>Study flow chart: generation of allocation sequence, enrollment and assignment was done by AD.</p

Predialysis hematocrit, antithrombine, CRP and applied volumes and compression times: median and interquartile range.

<p>Abbreviations: IN₀: tinzaparin injection before the start of the session at the inlet blood line; IN₅: injection 5 min after the start of the session at the inlet blood line and OUT₀: injection before the start of the session at the outlet blood line; C Reactive Protein (CRP.)</p><p>Comparison between schedules: no significant differences.</p><p>Predialysis hematocrit, antithrombine, CRP and applied volumes and compression times: median and interquartile range.</p

Delta transmembrane pressure (TMP) in relation to hemoconcentration (BVS), anti-Xa-activity and endogenous thrombin potential (ETP).

<p>Delta TMP is inversely correlated with hemoconcentration (p<0.0001, Spearman r = -0.68), no significant correlation between delta TMP and anti-Xa level or ETP at 240 min.</p

Endogenous Thrombin Potential (ETP): median and interquartile range.

<p>Abbreviations: IN₀: tinzaparin injection before the start of the session at the inlet blood line; IN₅: injection 5 min after the start of the session at the inlet blood line and OUT₀: injection before the start of the session at the outlet blood line.</p><p>Endogenous Thrombin Potential (ETP): median and interquartile range.</p

Uremic toxin concentrations.

<p>mg/dL, except urea in g/L, β₂M in µg/mL, and ADMA and SDMA in µmol/L.</p><p>Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric dimethylarginine, UA: uric acid, β₂M: beta-2-microglobulin, HA: hippuric acid, IS: indoxyl sulfate, IAA: indole acetic acid, PCS: <i>p</i>-cresylsulfate, PCG: <i>p</i>-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.</p

Multifactor analysis: covariates with cumulative R-value.

<p>Empty cells indicate that the correlation analysis did not include other elements that contributed significantly.</p

P and R-values for Spearman correlations between the solute concentrations and the different patient characteristics.

<p>Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric dimethylarginine, UA: uric acid, β₂M: beta-2-microglobulin, HA: hippuric acid, IS: indoxyl sulfate, IAA: indole acetic acid, PCS: <i>p</i>-cresylsulfate, PCG: <i>p</i>-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.</p><p>BW: body weight, PNA: protein equivalent of nitrogen appearance, RRF: residual renal function.</p><p>P<0.05 is indicated in bold. R values only shown in case of significant P.</p

Reduction ratio of urea and beta2microglobulin in relation to anti-Xa activity and ETP.

<p>Reduction ratio (RR) of urea (unfilled triangles) and beta2microglobulin (BETA2M) (filled triangles) in sessions with anti-Xa activity above or equal vs. below 0.3 IU/mL and detectable (ETP > 0) vs undetectable ETP (ETP = 0) at 240 min. Comparison between groups: * p<0.001.</p

Anti-Xa activity: median and interquartile range.

<p>Abbreviations: IN₀: tinzaparin injection before the start of the session at the inlet blood line; IN₅: injection 5 min after the start of the session at the inlet blood line and OUT₀: injection before the start of the session at the outlet blood line.</p><p>Anti-Xa activity: median and interquartile range.</p

Endogenous thrombin potential (ETP) in relation to anti-Xa activity.

<p>Endogenous thrombin potential (ETP) in relation to anti-Xa activity.</p